Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

TACTIVE-U: uno studio per conoscere il medicinale in studio (Vepdegestrant) quando somministrato con altri medicinali a persone con cancro al seno avanzato o metastatico. (Sottostudio C)

23 ottobre 2026 aggiornato da: Pfizer

TACTIVE-U: UNO STUDIO UMBRELLO IN APERTO DI FASE 1B/2 SULLA SICUREZZA ED L'EFFICACIA PER INDAGARE LA TOLLERABILITÀ, LA PK E L'ATTIVITÀ ANTITUMORALE DEL VEPDEGESTRANT (ARV-471/PF-07850327), UNA PROTEOLISI ORALE CHE MIRA ALLA CHIMERA, IN COMBINAZIONE CON ALTRI TRATTAMENTI ANTICANCRO IN PARTECIPANTI DI 18 ANNI E ANNI CON CANCRO AL SENO AVANZATO O METASTATICO ER+, SOTTOSTUDIO C (ARV-471 IN COMBINAZIONE CON SAMURACICLIB)

The purpose of this study is to learn about the safety and effects of the study medicine called vepdegestrant. The safety and effects of vepdegestrant will be see when given with other medicines. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat.

The study is seeking for participants who have breast cancer that:

  • is hard to treat (advanced) and may have spread to other organs (metastatic). is sensitive to hormonal therapy (it is called estrogen receptor positive).
  • is no longer responding to treatments taken before starting this study.

This study is divided into separate sub-studies.

For Sub-Study C:

All the participants will receive vepdegestrant and a medicine called samuraciclib.

Vepdegestrant and samuraciclib will be taken once in a day by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicine is safe and effective.

Participant will continue to take vepdegestrant and samuraciclib until:

  • their cancer is no longer responding, or
  • side effects become too severe.

They will have visits at the study clinic about every 4 weeks.

Panoramica dello studio

Stato

Terminato

Condizioni

Descrizione dettagliata

C4891024 is a prospective, open-label, multicenter, Phase 1b/2 sub-study to evaluate the safety, antitumor activity, and PK of ARV-471 with samuraciclib in the treatment of participants with A/MBC. The sub-study is part of Umbrella platform, TACTIVE-U, comprising multiple sub-studies that independently evaluate ARV-471 in participants with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer. ARV-471 will act as the backbone therapy given in combination with other anticancer agents thought to have clinical relevance in ER+ breast cancer.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

11

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Bruxelles-capitale, Région de
      • Anderlecht, Bruxelles-capitale, Région de, Belgio, 1070
        • Institut Jules Bordet
    • Côte-d'or
      • Dijon, Côte-d'or, Francia, 21079
        • Centre Georges François Leclerc
      • Roma, Italia, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
    • Lombardy
      • Monza, Lombardy, Italia, 20900
        • Fondazione IRCCS San Gerardo dei Tintori
    • Arkansas
      • Fayetteville, Arkansas, Stati Uniti, 72703
        • Highlands Oncology Group
      • Rogers, Arkansas, Stati Uniti, 72758
        • Highlands Oncology Group
      • Springdale, Arkansas, Stati Uniti, 72762
        • Highlands Oncology Group
    • California
      • Palo Alto, California, Stati Uniti, 94304
        • Stanford Women's Cancer Center
      • Palo Alto, California, Stati Uniti, 94304
        • Clinical and Translational Research Unit (CTRU)
      • Palo Alto, California, Stati Uniti, 94304
        • Stanford Cancer Institute - Clinical Trials Office
    • Colorado
      • Fort Collins, Colorado, Stati Uniti, 80524
        • UCHealth Poudre Valley Hospital
      • Fort Collins, Colorado, Stati Uniti, 80528
        • UCHealth Harmony
      • Greeley, Colorado, Stati Uniti, 80634
        • UCHealth Greeley Hospital
      • Loveland, Colorado, Stati Uniti, 80538
        • UCHealth - Medical Center of the Rockies
    • Illinois
      • Shiloh, Illinois, Stati Uniti, 62269
        • Memorial Hospital East
      • Shiloh, Illinois, Stati Uniti, 62269
        • Siteman Cancer Center - Shiloh
    • Missouri
      • City of Saint Peters, Missouri, Stati Uniti, 63376
        • Siteman Cancer Center - St Peters
      • Creve Coeur, Missouri, Stati Uniti, 63141
        • Siteman Cancer Center - West County
      • Florissant, Missouri, Stati Uniti, 63031
        • Siteman Cancer Center - North County
      • St Louis, Missouri, Stati Uniti, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University School of Medicine - Siteman Cancer Center
      • St Louis, Missouri, Stati Uniti, 63129
        • Siteman Cancer Center - South County

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Histological or cytological diagnosis of breast cancer. At time of enrollment this must not be amendable to surgical resection with curative intent (≥1% ER+ stained cells as per local practice on the most recent tumor biopsy HER2- tumor by IHC or in-situ hybridization per ASCO/CAP).
  • prior anticancer therapies: up to 2 lines of prior therapies for advanced/metastatic disease; 1 line of any CDK4/6 inhibitor-based regimen is required (in any setting eg adjuvant, metastatic)
  • at least 1 measurable lesion as defined by RECIST v1.1.
  • ECOG PS ≤1.

Exclusion Criteria:

  • visceral crisis at risk of life-threatening complications in the short term
  • known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions.
  • newly diagnosed brain metastases, or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 28 days prior to enrollment in the of study.
  • history of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix.
  • inflammatory breast cancer
  • impaired cardiovascular function or clinically significant cardiovascular diseases
  • concurrent administration of medications, food, or herb supplements that are strong inhibitors/inducers of CYP3A, strong CYP2D6 inhibitors and drugs known to predispose to Torsade de Pointes or QT interval prolongation.
  • renal impairment, not adequate liver function and/or bone marrow function
  • known active infection

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: ARV-471 in combination with Samuraciclib

ARV-471 administered orally QD continuously and Samuraciclib administered orally QD continuously on 28-day cycles

Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Altri nomi:
  • ARV-471 / PF-07850327

Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Phase 1b: Number of Participants With Dose Limiting Toxicities
Lasso di tempo: 28 days

Dose Limiting Toxicities rate for ARV-471 in combination with Samuraciclib, estimated based on data from DLT-evaluable participants during the DLT observation period (Cycle 1).

28 days
Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.
Lasso di tempo: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)

Steady-state Area under the plasma concentration versus time curve (AUCtau) of ARV-471 with and without coadministration of samuraciclib

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.
Lasso di tempo: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)

Steady-state Peak Plasma concentration ( Cmax) of ARV-471 with and without coadministration of samuraciclib

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
Phase 2: Percentage of Participants With Objective Response by investigator assessment
Lasso di tempo: Up to approximately 1 year

Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

Up to approximately 1 year
Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.
Lasso di tempo: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Single dose AUC0-72 of samuraciclib with and without coadministration of ARV 471.

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))
Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.
Lasso di tempo: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Single dose Cmax of samuraciclib with and without coadministration of ARV 471.

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Phase 1b, Drug drug interaction and Phase 2: Evaluation of Safety and Tolerability of ARV-471 in combination with Samuraciclib
Lasso di tempo: First study drug dose through a minimum of 28 Days After Last study drug administration

AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to ARV-471 in combination with samuraciclib.

Laboratory test abnormalities as characterized by type, frequency, intensity (as graded by NCI CTCAE version 5.0), and timing.

Changes from baseline for the ECG parameters heart rate, QTcF, PR interval, and QRS complex will be summarized by treatment and time. The frequency of uncorrected QT values above 500 ms will be tabulated.

First study drug dose through a minimum of 28 Days After Last study drug administration
Phase 1b: To evaluate antitumor activity of ARV-471 in combination with samuraciclib
Lasso di tempo: Up to approximately 1 year

Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

Up to approximately 1 year
Phase 1b and Phase 2: Duration of Response by investigator assessment.
Lasso di tempo: Up to approximately 1 year

Duration of Response (DoR) is defined for participants with confirmed OR (CR or PR) as the time from the first documentation of OR to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

Up to approximately 1 year
Phase 1b and Phase2: Percentage of participants with Clinical Benefit Response by investigator assessment.
Lasso di tempo: Up to approximately 1 year

Clinical Benefit Response (CBR) is defined as the proportion of participants with Best Overall Response of confirmed CR or PR at any time, or Stable Disease (SD) ≥24 weeks

Up to approximately 1 year
Phase 1b and Phase 2: Progression Free Survival by investigator assessment.
Lasso di tempo: Up to approximately 1 year

Progression Free Survival (PFS) is defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurs first.

Up to approximately 1 year
Phase 1b and Phase 2: Plasma concentrations of ARV-471 and samuraciclib.
Lasso di tempo: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

To evaluate the plasma exposure of ARV-471 and samuraciclib when ARV-471 and samuraciclib are given in combination.

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471
Lasso di tempo: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

AUCtau of ARV-471 with and without co-administration of samuraciclib

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471
Lasso di tempo: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

Cmax of ARV-471 with and without co-administration of samuraciclib

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 2:ctDNA plasma quantitative changes from pre-treatment
Lasso di tempo: At predefined intervals throughout the treatment period, up to cycle 3 (each cycle is 28 days) and end of treatment

To assess changes from baseline levels in plasma ctDNA with treatment and to evaluate potential predictability of their associations with clinical outcomes.

At predefined intervals throughout the treatment period, up to cycle 3 (each cycle is 28 days) and end of treatment
Phase 2: To evaluate the correlation between TP53 mutation status and antitumor activity
Lasso di tempo: Screening

Participants classified on basis of pathological TP53 mutation detected or not detected.

Screening
Phase 2: Overall Survival
Lasso di tempo: Through study completion, up to approximately 3 year

Overall Survival (OS) is defined as the time from the date of first dose of study interventions to the date of death due to any cause

Through study completion, up to approximately 3 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Pfizer CT.gov Call Center, Pfizer

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 gennaio 2024

Completamento primario (Effettivo)

10 settembre 2026

Completamento dello studio (Effettivo)

10 settembre 2026

Date di iscrizione allo studio

Primo inviato

16 ottobre 2023

Primo inviato che soddisfa i criteri di controllo qualità

4 novembre 2023

Primo Inserito (Effettivo)

9 novembre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

27 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • C4891024
  • 2023-507125-41-00 (Identificatore di registro: CTIS (EU))
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi